jRCT2041240173招募中不适用
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 726
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Sign and date the Tissue Prescreening ICF, prior to HER2 and PD-L1 CPS central testing. Sign and date the Main Screening ICF, prior to the start of any trial-specific qualification procedures. Sign anddate the Optional PGx ICF (included in the Main Screening ICF) prior to any PGx procedure.
- •Adults >=18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old.
- •Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma histologically confirmed by pathology report. Prior treatment in the perioperative and/or adjuvant setting is permissible, provided there is >6 months between the end of perioperative or neoadjuvant treatment and the diagnosis of recurrent disease.
- •Note: Prior use of IO (ie, anti-PD-1/PD-L1) therapy in the (neo)adjuvant setting is allowed as long as there is >6 months between the end of IO therapy and the diagnosis of recurrent disease.
- •Centrally determined HER2-positive (IHC 3+ or IHC 2+/ISH-positive) gastric or GEJ cancer as classified by the American Society of Clinical Oncology-College of American Pathologists for GC on a tumor biopsy as detected by prospective central test on new (core, incisional, excisional biopsy) or existing tumor tissue taken at the time of diagnosis of locally advanced or metastatic disease.
- •Note: Archival samples taken from a previous diagnostic or surgical biopsy not previously irradiated can be accepted. Details pertaining to tumor tissue submission can be found in the Study Laboratory Manual.
- •All participants must provide a tumor sample for tissue-based IHC staining to centrally determine HER2 expression, PD-L1 CPS, and other correlatives. The mandatory FFPE tumor sample can be from either the primary tumor or metastatic biopsy. Specimens with limited tumor content (as centrally determined) and cytology samples are inadequate for defining tumor HER2 and PD-L1 status.
- •At least 1 target measurable lesion on CT or MRI, assessed by the investigator based on RECIST v1.
- •Lesions situated in a previously irradiated area are considered measurable if progression hasbeen shown in such lesions.
- •LVEF >=50% within 28 days before randomization.
排除标准
- •Prior exposure to other HER2-targeting therapies (including ADCs).
- •Lack of physiological integrity of the upper gastrointestinal tract (ie, severe Crohn disease that results in malabsorption) or malabsorption syndrome that would preclude feasibility of oral chemotherapy (ie, capecitabine).
- •Known DPD enzyme deficiency.
- •Note: Screening for DPD deficiency should be conducted per local requirements.
- •Contraindications to trastuzumab, 5-FU, capecitabine, cisplatin, or oxaliplatin treatment as per local label.
- •Medical history of myocardial infarction within 6 months before randomization or symptomatic CHF (New York Heart Association Class II to IV). Participants with troponin levels above ULN at Screening (as defined by the manufacturer) and without any myocardial infarction-related symptoms should have a cardiologic consultation during the Screening Period to rule out myocardial infarction.
- •Has a corrected QT interval (QTcF) prolongation to >470 ms (females) or >450 ms (males) based on the average of the screening triplicate 12-lead ECG.
- •Has a history of (non-infectious) ILD/pneumonitis that required steroids, has currentILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
- •Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the trial randomization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc).
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: From date of randomization to the date of radiographic disease progression or death due to any cause, up to 59 months
PFS is defined as the time interval from the date of randomization to the date of radiographic disease progression as assessed by blinded independent central review (BICR) based on RECIST v1.1 or death due to any cause
次要结局
- Overall Survival (OS)(From date of randomization to the date of death due to any cause, up to 59 months)
研究者
相似试验
已完成
不适用
eoadjuvant chemotherapy using the TXL and CDDP followed by surgery for advanced gastric cancer - Phase IIadvanced gastric cancerJPRN-C000000278TC therapy for gastric cancer study group50
已完成
2 期
Exploratory study of Xeloda+CDDP(XP)+Trastuzumab therapy for advanced gastric cancer with HER2 positive CTCsAdvanced gastric cancer patients with HER2 over expression CTCs whose primary lesion is HER2 negative or of unknown HER2 statusJPRN-UMIN000008622The Cancer Institute Hospital of JFCR30
终止
2 期
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue SarcomaSarcomaNCT01189253European Organisation for Research and Treatment of Cancer - EORTC133
已完成
2 期
Durvalumab and Tremelimumab in Patients With Advanced Rare TumoursAdvanced Rare TumoursNCT02879162Canadian Cancer Trials Group140
已完成
不适用
Treatment with standard chemotherapy and dendritic cells pulsed with WT1 peptides for pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000032386The Jikei University School of Medicine, Kashiwa Hospital, Division of Gastroenterology & Hepatology, Department of Internal Medicine10